Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Double-masked, Multicenter, Randomized, Active Treatment-controlled Study of the Efficacy and Safety of 0.5 mg and 2.0 mg Ranibizumab Administered Monthly or on an As-needed Basis (PRN) in Patients With Subfoveal Neovascular Age-related Macular Degeneration

NCT00891735 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT00891735
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00891735 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Double-masked, Multicenter, Randomized, Active Treatment-controlled Study of the Efficacy and Safety of 0.5 mg and 2.0 mg Ranibizumab Administered Monthly or on an As-needed Basis (PRN) in Patients With Subfoveal Neovascular Age-related Macular Degeneration
Lead sponsor
Genentech, Inc.
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2009
Completion date
August 31, 2012
Enrollment
1,097 (actual)
Sites
99

Conditions

As the registry lists them; a condition with its own page is linked.

age-related macular degeneration